Biden's Drug Pricing Administrative Actions Could Focus On Medicare Demos
Center for American Progress suggests pricing reforms for the 'next Administration' in lieu of legislation.
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The latest flurry of Executive Order activity on drug pricing reinforces the message that the President wants to own the headlines for being tough on the drug industry as Election Day looms. Looking for substance beyond that goal is a fool’s errand – but the headlines could still have significant consequences no matter who wins in November.
The US Democratic Party will not be rallying around ‘Medicare for All’ in November. But the absence of a push for a single payer system is about the only good news for drug companies in the ‘unity platform’ released by presumptive Presidential nominee Joe Biden and his defeated rival Bernie Sanders.